Finoriq research workspace
ANI PHARMACEUTICALS INC (ANIP) Company Overview
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded. Review ANIP filings, fundamentals, valuation, and ownership on Finoriq.
Company Snapshot
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
- Company
- ANI PHARMACEUTICALS INC (ANIP)
- Ticker
- ANIP
- Market Cap
- $1.8B
- Latest Price
- $78.2
- Industry
- Biotech & Pharma
ANI PHARMACEUTICALS INC (ANIP) Current Valuation Metrics
Static valuation preview for ANI PHARMACEUTICALS INC (ANIP). Market data retrieved 2026-07-08. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/EMarket cap divided by latest TTM net income. | 20.7x | Net Income | TTM Q1 2026 |
| P/SMarket cap divided by latest TTM revenue. | 2.07x | Revenue | TTM Q1 2026 |
| P/Operating Cash FlowMarket cap divided by latest TTM operating cash flow. | 9.16x | Operating Cash Flow | TTM Q1 2026 |
| Earnings YieldLatest TTM net income divided by market cap. | 4.8% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | 10.9% | Operating Cash Flow | TTM Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.